CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for damaging biological material. Therefore, the global bioprinting community will greatly benefit from Atelerix products that allow for room-temperature storage and shipping of sensitive primary cells, iPSC-derived cells, multicellular models and especially cell-laden bioprinted constructs, such as those manufactured with CELLINK’s range of innovative 3D bioprinters.
“Ultimately, it’s the simple things that make a difference,” says Dr. Himjyot Jaiswal, CELLINK’s Scientific Team Lead for Tissue Engineering and Cell Biology. “This technology will enable scientists to ‘lower the barrier’ for initiating lab-to-lab collaborations that require ‘living material’ to be moved from one researcher to another.”
Atelerix’s range of innovative products, including BeadReady™ (used for cells in suspension), WellReady™ (used for plated cells and cell-laden bioprinted constructs) and TissueReady™ (used for tissue samples and larger cell-laden bioprinted constructs), will be available for purchase from CELLINK, so that the research community may procure all their bioprinting requirements in one place.
“The news of two of the most exciting and innovative life science companies coming together to enable the scientific community to ship biofabricated 3D models is incredibly important,” says Steve Swioklo, CSO of Atelerix. “The manufacture of cell-laden bioprinted constructs is one of the fastest growing application areas in today’s life science industry, but it is hampered by the need to ship bioprinted tissues and models from one laboratory to another whilst preserving cell viability and fine structure integrity. Atelerix’s products now make that possible.”
CELLINK CSO Dr. Itedale Namro Redwan agrees, “We are very pleased to announce this very important partnership with Atelerix. The technology that they provide for shipping 3D bioprinted constructs, tissues and cells at room temperature will have a major impact on how collaborations between labs are executed—and even on how tissues and organs are transported from lab-to-clinic or clinic-to-clinic. We see the Atelerix range of products complementing our bioprinter and bioink portfolio well.”Article sourced from atelerix.co.uk